Filter case studies by:

Share this
  • Share on Twitter
  • Share on facebook

Elias Mossialos

Read their case study

Resources related to the case study:

About the author and department

Personal webpage:

Social Policy Department:

LSE Health and Social Care:

Relevant research

Mossialos, E., Kanavos, P., Abel-Smith, B. (1994) Policy Options for Pharmaceutical Research and Development in the European Community. Brussels: European Parliament – Science and Technology Options Assessment Programme.

Mrazek, M., Mossialos, E. (2003) Stimulating pharmaceutical research and development for neglected diseases, Health Policy 64 (1). pp. 75-88. LSE Research Online number 20087.

Brogan, D, Mossialos, E (2006) Applying the concepts of financial options to stimulate vaccine development, Nature Reviews, 5, 641-647. LSE Research Online number 19345.

Mossialos, E; Morel, C; Edwards, S; Berenson, J; Gemmill-Toyama, M; Brogan D (2010) Policies and Incentives for Promoting Innovation in Antibiotic Research, WHO and European Observatory on Health Systems and Policies. LSE Research Online number 28751.

Morel C, Mossialos E (2010) Stoking the antibiotic pipeline. British Medical Journal, 340, 115-118. LSE Research Online number 28555.

Brogan D, Mossialos E. (2013) Incentives for New Antibiotics: The Options Market for Antibiotics (OMA) Model, Globalization and Health 9 (58). DOI: 10.1186/1744-8603-9-58. Available at

Morel, C and Mossialos,E ‘Incentives for promoting R&D in novel antibiotics: How do proposed incentive mechanisms compare according to key criteria?’ 23 May 2011, ReAct conference on Collaboration for Innovation – The Urgent Need for New Antibiotics, Brussels.

Evidence of impact

Council of the European Union, ‘Council Conclusions on innovative incentives for effective Antibiotics’, 1 December 2009, para 13 acknowledges the LSE Report.

Transatlantic Taskforce on Antimicrobial Resistance: Recommendations for future collaboration between the U.S. and EU, 2011.

Burki, T. (2010) Push and pull of antibiotic development, The Lancet Infectious Diseases, 10, 1, 12-13.

Harrell, E. (2009) The desperate need for new antibiotics, TIME, 1 October 2009.,8599,1926853,00.html

Tutton, M. (2009) New research warns penicillin 'becoming obsolete'. CNN, 26 January 2010, published on 1 October, 2009. Cooper, M. and Shlaes D. (2011) Fix the antibiotics in pipelines, Nature, 472, 32.

‘EFPIA contributes to IMI €223.7 million programme to tackle Antibiotic resistance’. Brussels: European Federation of Pharmaceutical Industries and Associations, 24 May 2012.

Expert testimony. US Congress House Committee on Energy and Commerce Subcommittee on Health. Washington DC: US Congress; 9 June 2010 and 8 March 2012 (B. Spellberg, Infectious Disease Society of America, expert testimony and B. Eistenstein Senior Vice President, Scientific Affairs, Cubist Pharmaceuticals Inc.)Platsis G (Director of the Research Center at the National Defense Foundation) & Kavanagh S. (2011) Keeping Pace: Protecting Our Troops and Our Population by Incentivizing Antimicrobial Research and Development. Washington DC: National Defense Foundation.

Merck & Co., Inc. Public Policy Statement: Antimicrobial Resistance, July 2015.

Relevant video and audio

On health policy and innovating for longevity:

Read their case study